728 filings
Page 9 of 37
424B3
KA
Kineta Inc
5 Dec 22
Prospectus supplement
9:22am
425
KA
Kineta Inc
1 Dec 22
Business combination disclosure
4:04pm
8-K
KA
Kineta Inc
1 Dec 22
Kineta to Present KVA12123 VISTA Blocking Immunotherapy Program at Antibody Engineering and Therapeutics Conference
4:01pm
425
KA
Kineta Inc
29 Nov 22
Business combination disclosure
4:03pm
8-K
KA
Kineta Inc
29 Nov 22
Kineta to Participate in JMP Securities Hematology and Oncology Summit
4:01pm
425
KA
Kineta Inc
28 Nov 22
Business combination disclosure
4:03pm
8-K
KA
Kineta Inc
28 Nov 22
Regulation FD Disclosure
4:01pm
SEC STAFF
KA
Kineta Inc
17 Nov 22
SEC staff action: Order
12:00am
425
KA
Kineta Inc
15 Nov 22
Business combination disclosure
4:03pm
8-K
KA
Kineta Inc
15 Nov 22
Kineta Announces FDA Acceptance of Investigational New Drug (IND) Application for KVA12123 for the Treatment of Advanced Solid Tumors
4:02pm
425
KA
Kineta Inc
14 Nov 22
Business combination disclosure
8:50am
10-Q
2022 Q3
KA
Kineta Inc
Quarterly report
14 Nov 22
8:44am
8-K
KA
Kineta Inc
14 Nov 22
Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments
8:37am
EFFECT
KA
Kineta Inc
14 Nov 22
Notice of effectiveness
12:15am
424B3
KA
Kineta Inc
10 Nov 22
Prospectus supplement
4:21pm
CORRESP
KA
Kineta Inc
8 Nov 22
Correspondence with SEC
12:00am
S-4/A
KA
Kineta Inc
Registration of securities issued in business combination transactions (amended)
4 Nov 22
4:49pm
CORRESP
KA
Kineta Inc
4 Nov 22
Correspondence with SEC
12:00am
UPLOAD
KA
Kineta Inc
1 Nov 22
Letter from SEC
12:00am
425
KA
Kineta Inc
27 Oct 22
Business combination disclosure
7:15am